1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)-
Multiple Myeloma
University Health Network, Torontoprotein_peptidePhase 2Active
CCC
50/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 59/ 100
Competitive context
497 Active assets in the Multiple Myeloma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Jonsson Comprehensive Cancer Center | Phase 4 | BBB |
Inno-206 University of Arkansas | Phase 3 | BBB |
Hyaluronidase fihj Massachusetts General Hospital | Phase 4 | BBB |
Busulphan M.D. Anderson Cancer Center | Phase 4 | BBB |
Filanesib PETHEMA Foundation | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →